Clinical Trials Logo

Choroideremia clinical trials

View clinical trials related to Choroideremia.

Filter by:

NCT ID: NCT02341807 Completed - Choroideremia Clinical Trials

Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations

Start date: January 15, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.

NCT ID: NCT02077361 Completed - Choroideremia Clinical Trials

An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia

Start date: April 2015
Phase: Phase 1/Phase 2
Study type: Interventional

A project has been developed in Edmonton, Alberta, Canada to enable male patients with choroideremia to access a clinical trial that replaces the defective gene with a normal copy. This experiment is designed to show that the transfer of a normal copy of the gene to the eye is not only safe but may improve the sight of patients. Only Canadian subjects who meet criteria will be recruited.

NCT ID: NCT01864486 Completed - Clinical trials for Retinitis Pigmentosa

Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy

IRIS-1
Start date: April 2013
Phase: N/A
Study type: Interventional

This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System (IRIS V1)

NCT ID: NCT01603576 Completed - Clinical trials for Retinitis Pigmentosa

Pilot Study of a Suprachoroidal Retinal Prosthesis

Start date: May 2012
Phase: N/A
Study type: Interventional

This study will be an initial proof of concept study, to evaluate safety and efficacy of a prototype suprachoroidal retinal implant

NCT ID: NCT01461213 Completed - Choroideremia Clinical Trials

Gene Therapy for Blindness Caused by Choroideremia

Start date: October 2011
Phase: Phase 1/Phase 2
Study type: Interventional

- Primary objective: To assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in 12 patients with a diagnosis of choroideremia. - Secondary Objective: To identify any therapeutic benefit as evidenced by a slowing down of the retinal degeneration assessed by functional and anatomical methods in the treated eye compared to the control eye 24 months after gene delivery.